Study Highlights Challenge of Selecting Patients for Mesothelioma Immunotherapy

A new study is casting some doubt on the value of a protein called PD-L1 as a way to select mesothelioma patients for targeted immunotherapy. Several of the most promising new treatments for malignant mesothelioma, including pembrolizumab (Keytruda) and avelumab (Avastin), are designed to inhibit PD-L1, a protein cells used to evade detection by the immune system. PD-L1 inhibitors like Keytruda have become an important … Continue reading Study Highlights Challenge of Selecting Patients for Mesothelioma Immunotherapy »

Immunotherapy for Mesothelioma: Who Are the Best Candidates?

Immunotherapy is emerging as one of the most promising new treatment approaches for a wide range of cancers, including malignant pleural mesothelioma, the treatment-resistant lung-related cancer caused by asbestos exposure. Every year, more than 2,500 Americans are diagnosed with pleural mesothelioma. Most will die of the illness within 18 months, even with the most advanced chemotherapeutic, radiotherapeutic, and surgical treatments. But immunotherapy, which recruits the … Continue reading Immunotherapy for Mesothelioma: Who Are the Best Candidates? »

Three-Drug Combo is New Standard of Care for Pleural Mesothelioma in France

France has a new standard of care for people with unresectable malignant pleural mesothelioma. Along with the chemotherapy drugs cisplatin and pemetrexed (Alimta), French doctors are now regularly also using bevacizumab (Avastin) to boost the effectiveness of mesothelioma chemotherapy. The addition of Avastin to standard mesothelioma care came after the 2016 French-led mesothelioma avastin cisplatin pemetrexed study (MAPS) showed that the VEGF inhibitor improved mesothelioma … Continue reading Three-Drug Combo is New Standard of Care for Pleural Mesothelioma in France »

Inflammation Marker May Predict Mesothelioma Prognosis

The ratio of neutrophils to lymphocytes – a way of measuring inflammation in the body of people with malignant pleural mesothelioma – may help doctors predict how well they will respond to treatment. That is the conclusion of mesothelioma researchers at China’s Sichuan University. In a new article in the journal Oncotarget, the team observed that NLR has been associated with survival in other types … Continue reading Inflammation Marker May Predict Mesothelioma Prognosis »

Using Immune Cells to Predict Mesothelioma Outcomes

Immune system cells may be some of the best predictors of mesothelioma outcomes, according to a group of British scientists. A new article in the British Journal of Cancer has found a close association between outcomes in people with different subtypes of malignant mesothelioma and the levels of different types of immune system cells in their bodies. Measuring Immune Response To create the experiment, researchers … Continue reading Using Immune Cells to Predict Mesothelioma Outcomes »

These Proteins Appear to Shorten Mesothelioma Survival

New evidence suggests that mesothelioma patients whose tumors express two particular proteins do not live as long as other mesothelioma patients. An international team of scientists including mesothelioma researchers at the National Cancer Institute say ALCAM (also called CD166) and PD-L1 (CD274) are both associated with “significantly decreased” survival in pleural mesothelioma. Understanding ALCAM and PD-L1 ALCAM is a type I transmembrane protein that regulates … Continue reading These Proteins Appear to Shorten Mesothelioma Survival »

Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival

A large international clinical trial of the immunotherapy drug tremelimumab as a second- or third-line treatment option for malignant mesothelioma has produced some disappointing news. Drug maker AstraZeneca has just released an update on the ongoing DETERMINE trial which suggests that the survival rates are roughly the same for previously-treated mesothelioma patients whether they later received treatment with tremelimumab or a placebo. What is Tremelimumab? … Continue reading Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival »

MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma

Australian scientists say it may be possible to artificially reduce the levels of a protein that helps mesothelioma tumors hide from the immune system. The new research published in the Journal of Thoracic Oncology could open the door to more effective immunotherapy treatments for pleural mesothelioma. The Importance of PD-L1 Expression A cell surface protein called PD-L1 is key to the effectiveness of several new … Continue reading MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma »

Altered Viruses May Help Boost Immunotherapy for Malignant Mesothelioma

Viruses may soon be playing a bigger role in the fight against malignant mesothelioma and other thoracic cancers. A pair of biologists from Minnesota say there is evidence that, in addition to killing mesothelioma cells directly, specific kinds of altered viruses might help make mesothelioma immunotherapy treatment more effective. How Does Immunotherapy Work? Like many other types of cancer, mesothelioma tumors are able to grow unchecked … Continue reading Altered Viruses May Help Boost Immunotherapy for Malignant Mesothelioma »

Immunotherapy and Radiation: A Powerful Mesothelioma Combo

New research suggests that, in the battle against malignant pleural mesothelioma, a treatment combining of immunotherapy drugs with radiotherapy may be a powerful new weapon. Researchers at the University of Pennsylvania reached that conclusion after reviewing the few existing studies on this emerging multimodal mesothelioma treatment for an article in Translational Lung Cancer Research.   Current available treatments for pleural mesothelioma, an aggressive lung-related cancer,  include surgical resection, … Continue reading Immunotherapy and Radiation: A Powerful Mesothelioma Combo »

Get your free copy of
“Surviving Mesothelioma” Today!